Dr Reddy's Laboratories today informed the BSE that it has launched Levofloxacin tablets, a bioequivalent generic version of Levaquin tablets in the US on June 20, 2011. The company's generic drug has received approval from the United States Food and Drug Administration (USFDA). It has launched the Levofloxacin tablets in 250 mg, 500 mg and 750 mg strengths.
The Levaquin brand had US sales of approximately $1.1 billion for the twelve month period ending March 2011 as per IMS Health, a pharma consultancy.
Dr Reddy's scrip is currently trading at Rs 1,503.80 on the BSE, down 0.69%, over previous close of Rs 1,514.25.
